Wisconsin Alumni Research Foundation

WizMediBio Signs Contract with the Wisconsin Alumni Research Foundation (WARF) for Botulinum Toxin Strain

Retrieved on: 
Tuesday, April 9, 2024
A1, Beauty, Research, University, GMP, Wisconsin Alumni Research Foundation, Commerce, Patent, Jan Vansina, WARF, FDA, Pharmaceutical industry

The A1 botulinum toxin currently dominates the market and as a novel subtype, A6 presents itself as a challenger.

Key Points: 
  • The A1 botulinum toxin currently dominates the market and as a novel subtype, A6 presents itself as a challenger.
  • Therefore, the future course of the A6 strain as a BOTULINUM TOXIN provides a new opportunity in the botulinum field.
  • The company aims to capture the botulinum toxin market based on maximized utilization of its distribution network and experience.
  • "We will enhance the global market, especially the U.S., with novel botulinum toxin products," said Choi Yong-hoon, the CEO of WizMedi Bio.

Cellectar Biosciences Reports Financial Results for Year Ended 2023 and Provides a Corporate Update

Retrieved on: 
Wednesday, March 27, 2024
Research, NCI, AON, Development, Sarcoma, Disease, Neuroblastoma, Shareholder, Patient, CNS, Fast Track, Cash, SBIR, NDA, Syndrome, Cancer, MRR, CLR, BNS, University, Head, External beam radiotherapy, Cure, Wisconsin Alumni Research Foundation, WAM, HERE, Completeness, Safety, Tat, Intellectual property, Patent, PLE, WARF, Symantec Endpoint Protection, Tranche, UW, Pharmaceutical industry

FLORHAM PARK, N.J., March 27, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of cancer, today announced financial results for the year ended December 31, 2023, and provided a corporate update.

Key Points: 
  • FLORHAM PARK, N.J., March 27, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of cancer, today announced financial results for the year ended December 31, 2023, and provided a corporate update.
  • Net cash used in operating activities during the twelve months ended December 31, 2023, was approximately $32.4 million.
  • General and Administrative Expense: G&A expense for the year ended December 31, 2023, was $10.7 million, compared to $9.6 million for the year ended December 31, 2022.
  • Cellectar management will host a conference call for investors today, March 14, 2024, beginning at 8:30 am Eastern Time to discuss these results and answer questions.

Ginkgo Bioworks Acquires Modulus Therapeutics' Cell Therapy Assets to Strengthen Next-Gen CAR Designs

Retrieved on: 
Tuesday, April 2, 2024
Cell engineering, Immunotherapy, Partnership, Library, Research, DNA, Gene, Acquisition, Society, Wisconsin Alumni Research Foundation, Therapy, Modulus, Safety, Poster, SITC, Cell, WARF, Autoimmunity, Annual general meeting, Vaccine

Modulus Therapeutics is a cell engineering company focused on the design of next-generation cell therapies for autoimmune diseases.

Key Points: 
  • Modulus Therapeutics is a cell engineering company focused on the design of next-generation cell therapies for autoimmune diseases.
  • In contrast to legacy cell therapy design, the company uses a combinatorial approach to build and screen cell therapy components that work in concert with one another to yield novel cell behaviors.
  • Jason Kelly, CEO and co-founder of Ginkgo Bioworks: "Modulus Therapeutics has built an array of incredible cell therapy assets that we are excited to add into the significant cell therapy capabilities Ginkgo has developed to date.
  • Ginkgo expects Modulus' cell therapy assets to help Ginkgo continue to strengthen its CAR-T research & development offerings.

Cellectar Biosciences Expands Iopofosine I 131 Collaboration with Wisconsin Alumni Research Foundation

Retrieved on: 
Tuesday, December 19, 2023
WARF, UW, Neuroblastoma, Sarcoma, Jan Vansina, Wisconsin Alumni Research Foundation, Cancer, University, NCI, History

FLORHAM PARK, N.J., Dec. 19, 2023 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced a new licensing agreement with the Wisconsin Alumni Research Foundation (WARF) for intellectual property that was the result of collaborative research conducted at the University of Wisconsin-Madison (UW) with iopofosine I 131 in pediatric cancers.

Key Points: 
  • FLORHAM PARK, N.J., Dec. 19, 2023 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced a new licensing agreement with the Wisconsin Alumni Research Foundation (WARF) for intellectual property that was the result of collaborative research conducted at the University of Wisconsin-Madison (UW) with iopofosine I 131 in pediatric cancers.
  • Under the terms of the agreement, Cellectar has an exclusive license to develop and commercialize iopofosine in various pediatric solid cancers, such as high-grade glioma, neuroblastoma and sarcoma.
  • “This licensing agreement further strengthens our iopofosine I 131 patent portfolio and our industry leading position in radiopharmaceutical patent grants and applications.
  • It also expands our long-standing relationship with the University of Wisconsin.

Ubicept Raises $8M to Unlock Computer Vision in All Lighting Conditions by Counting Individual Photons

Retrieved on: 
Tuesday, July 25, 2023
Technology, Hardware, Other Technology, University of Wisconsin–Madison, Perception, PVP, University, Photon, MIT, Computer, Wisconsin Alumni Research Foundation, Logic, Cryptocurrency

Born out of the world-class labs of MIT and University of Wisconsin-Madison, Ubicept is redefining boundaries in the field of computer vision.

Key Points: 
  • Born out of the world-class labs of MIT and University of Wisconsin-Madison, Ubicept is redefining boundaries in the field of computer vision.
  • Traditional computer vision relies on a dated "still frame" approach, whereas Ubicept bypasses this old logic and directly leverages single-photon sensors to turn the individual photons that hit an imaging sensor into a reliable computer vision output.
  • The resulting perception system can operate in extreme lighting conditions, capture sharp images of high-speed motion, and even "see" around corners.
  • "Ubicept is the first company in the world with this "count individual photons" approach to computer vision.

WARF board welcomes three new trustees

Retrieved on: 
Monday, July 10, 2023
Data management, Translational Research Institute, Laboratory, University, UW, Engineer Research and Development Center, Collins, Wisconsin Alumni Research Foundation, Biomedical Research, United States Air Force Scientific Advisory Board, American Nurses Association, Research, Economics, Genentech, Medtronic, Retirement, NASA, Investment, Chairperson, Biology, DNAnexus, Richard C. Perry, Therapy, Jan Vansina, American Family Insurance, WARF, University of Wisconsin–Madison, Management, Nursing, Trustee

MADISON, Wis., July 10, 2023 /PRNewswire/ -- Asha Collins, Paul Leff and Thomas Tefft, three leading executives in the fields of biomedical research, investments and corporate medical device innovation, have joined the board of the Wisconsin Alumni Research Foundation (WARF).

Key Points: 
  • Asha Collins brings 18 years of biomedical research experience to the WARF Board of Trustees.
  • "I'm honored to join the WARF board and look forward to assisting the organization to further its worthy mission," says Leff.
  • "Asha, Paul and Tom bring tremendous experience to the WARF Board of Trustees," says Erik Iverson, WARF's CEO.
  • "All three are graduates of UW-Madison, have exemplary careers in their fields, and share the same dedication to the university as the other WARF trustees.

Realta Fusion Launches with $12 Million in Funding to Develop Fusion Energy

Retrieved on: 
Wednesday, May 31, 2023
U.S. Department of Energy, Office of Inspector General, University, U.S. Department of Defense Strategy for Operating in Cyberspace, Fusion, Temperature, WARF, ARPA, Wind, University of Wisconsin–Madison, Plasma, Professor, Wisconsin Alumni Research Foundation, Khosla Ventures, Physics, Khosla, BEAM, Lithium, Renewable energy, Rodels-Realta railway station

MADISON, Wis., May 31, 2023 /PRNewswire-PRWeb/ -- Realta Fusion, a new startup in fusion energy, today announced $12 million in financing to develop compact magnetic mirror fusion technology. The company raised a seed investment of $9 million led by Khosla Ventures and received an award of $3 million from the US Department of Energy's Fusion Development Program. The Wisconsin Alumni Research Foundation (WARF), through which Realta licensed its core technology, also participated in the seed round.

Key Points: 
  • Realta Fusion announces $12 million in funding, consisting of a $9 million seed round led by Khosla Ventures and a $3M award from the U.S. Department of Energy.
  • MADISON, Wis., May 31, 2023 /PRNewswire-PRWeb/ -- Realta Fusion, a new startup in fusion energy, today announced $12 million in financing to develop compact magnetic mirror fusion technology.
  • The company raised a seed investment of $9 million led by Khosla Ventures and received an award of $3 million from the US Department of Energy's Fusion Development Program.
  • In Realta, we saw a team that has made significant technical advances and can iterate quickly and cost-effectively to get to commercial fusion energy."

Ginkgo Bioworks and WARF Announce Partnership to Discover Next Generation GD2 CAR T-Cell Therapies

Retrieved on: 
Thursday, April 13, 2023
Neuroblastoma, DNA, CRISPR, Partnership, University, Therapy, Engineering, Wisconsin Alumni Research Foundation, Clinical trial, Bone marrow, Immunotherapy, ICD, Research, University of Wisconsin–Madison, CAR, Journal, Ginkgo, GD2, Cell engineering, Health, FDA, NYSE, WARF, Pharmaceutical industry, Vaccine, Cancer

MADISON, Wis. and BOSTON, April 13, 2023 /PRNewswire/ -- The Wisconsin Alumni Research Foundation (WARF), which has a mission of supporting research at the University of Wisconsin-Madison, and Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced a partnership to leverage Ginkgo's proprietary high-throughput combinatorial CAR discovery and screening platform with the aim of discovering next generation GD2 CAR T-cell therapies with improved persistence, proliferation, fitness, and other functional properties to improve efficacy for the treatment of solid tumors.

Key Points: 
  • Through this partnership, Ginkgo will collaborate with the University of Wisconsin-Madison researchers Professor Krishanu Saha, Ph.D., as principal investigator (PI) and Dr. Christian Capitini, M.D.
  • Under this collaboration, Ginkgo will use its pooled CAR screening platform to design and characterize novel intracellular signaling domains that prevent the exhaustion of T-cells in the GD2 solid tumor context.
  • In addition, Ginkgo and WARF plan to collaborate on the development of a pooled in vivo screening platform to advance novel CAR discovery further.
  • WARF and Ginkgo hope to work towards solving this challenge by utilizing Ginkgo's high-throughput combinatorial CAR discovery platform.

Craig J. Christianson Joins Water Street Healthcare Partners

Retrieved on: 
Wednesday, April 12, 2023
University of Wisconsin–Madison College of Agricultural and Life Sciences, 55 Water Street, Terso Solutions, Water, IBM, Growth, Promega, University, Water Street, Wisconsin Alumni Research Foundation, Investment, Pharmaceutical industry

CHICAGO, April 12, 2023 /PRNewswire/ -- Water Street Healthcare Partners , a strategic investor focused exclusively on the health care industry, announced today that Craig J. Christianson has joined the firm as an executive advisor.

Key Points: 
  • CHICAGO, April 12, 2023 /PRNewswire/ -- Water Street Healthcare Partners , a strategic investor focused exclusively on the health care industry, announced today that Craig J. Christianson has joined the firm as an executive advisor.
  • He will work with Water Street's team of health care executives and investment professionals to identify and pursue growth opportunities in life sciences businesses.
  • I'm excited to work with Water Street on building businesses that can make a positive impact in life sciences.
  • Water Street is actively pursuing opportunities to grow companies in three key health care sectors: health care services, medical products and diagnostics, and pharmaceuticals and life sciences.

Cellectar Reports Financial Results for Year Ended 2022 and Provides a Corporate Update

Retrieved on: 
Thursday, March 9, 2023
Macroglobulinemia, BCMA, Neoplasm, CLR, Wisconsin Alumni Research Foundation, Primary central nervous system lymphoma, NCI, State Administrative Expenses, Cash, Development, Diagnosis, Glioma, District court, Tat, Conference, Lead, DRS, Patient, Research, Hand, PLE, G&A, Cancer, Lymphoma, Comment, Travel, Marketing, Society, CNS, Intellectual property, Pharmaceutical industry, Cryptocurrency

FLORHAM PARK, N.J., March 09, 2023 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted treatments for cancer, today announced financial results for the year ended December 31, 2022 and provided a corporate update.

Key Points: 
  • FLORHAM PARK, N.J., March 09, 2023 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted treatments for cancer, today announced financial results for the year ended December 31, 2022 and provided a corporate update.
  • Presented preclinical data on the CLR 12120 series of targeted alpha therapies (TATs) at the 13th Annual World ADC Conference.
  • Net cash used in operating activities during the year ended December 31, 2022 was approximately $25.2 million.
  • Research and Development Expense: R&D expense for the year ended December 31, 2022 was approximately $19.2 million, compared to approximately $17.6 million for the year ended December 31, 2021.